Pathos AI has closed a $237 million Series E round led by Bristol Myers Squibb at a valuation of about $3 billion, and signed companion deals with Bristol Myers and Tempus AI to take its agentic drug-development platform, Foundry, into Alzheimer’s disease and other neurological conditions. Why it matters: a major drugmaker is not just buying software here — it is leading the financing and taking exclusive neuroscience rights to the platform, a clear sign big pharma now treats AI trial-steering as core infrastructure.
New York — October 23, 2026
What happened
Pathos AI announced two linked moves on Friday, October 23. It closed a $237 million Series E financing at a post-money valuation of approximately $3 billion, led by Bristol Myers Squibb with participation from existing investors. At the same time, it entered multi-year strategic collaborations with Bristol Myers Squibb (BMS) and Tempus AI to build a specialized dataset and agentic AI capabilities for Alzheimer’s disease and other neurological conditions — a new therapeutic area for a company whose platform was built and validated in oncology.
How the three-way deal is structured
Tempus will use the data infrastructure it built in oncology to create a comprehensive, de-identified, longitudinal dataset drawn from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time. Pathos will license that dataset from Tempus under a five-year, $55 million agreement, and point Foundry at it to generate and test hypotheses about disease biology and to design more targeted, adaptive clinical trials. BMS, in return for leading the round, gets non-exclusive strategic access to Foundry across its broader research portfolio, plus three-year exclusive rights to use the platform to support its neuroscience development programs.
What Foundry does, and where the money goes
Foundry runs thousands of specialized AI agents that pull together everything known about a drug program in real time — clinical data, genomics, biological specimen data, and the competitive landscape — and continuously update a probability-of-success calculation for each asset. Pathos says that lets it spot the patient sub-populations most likely to respond, pivot trial designs mid-course, and drop high-risk development paths early. The company credits Foundry with rapidly expanding its oncology pipeline to four active clinical assets through a series of recent transactions. The new capital will scale the platform and push those programs forward, with priority on moving JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, toward registrational studies, alongside pocenbrodib, the AstraZeneca-partnered AZD4241, and DO-2.
Why it matters
Most AI-drug deals are discovery partnerships: a model, a dataset, a press release. This one is structured differently. The customer led the funding round, took exclusivity in the new disease area, and is paying for the data layer through a partner — which suggests BMS wants Foundry embedded in how its neuroscience trials are designed, not rented for a pilot. The honest caveat is the usual one for this sector: every claim here is about improving the odds of trial success, and the proof only arrives when AI-steered programs actually read out. Pathos now has the capital, the data, and a top-tier pharma sponsor lined up behind that test.
Frequently asked questions
How much did Pathos AI raise, and at what valuation?
$237 million in a Series E round, at a post-money valuation of approximately $3 billion. Bristol Myers Squibb led the round, with existing investors participating.
What is Pathos Foundry?
Pathos’s AI platform for drug development. It uses thousands of specialized agents to synthesize clinical, genomic, specimen, and competitive data in real time, maintain probability-of-success estimates for each drug program, and guide decisions on patient selection and trial design.
What will Tempus AI contribute?
A de-identified, longitudinal dataset built from hundreds of thousands of patients with neurological conditions. Pathos is licensing it under a five-year, $55 million agreement.
What does Bristol Myers Squibb get?
Non-exclusive strategic access to Foundry across its broader portfolio, and three-year exclusive rights to use the platform for its neuroscience development programs, starting with Alzheimer’s disease.
Sources: Reuters; Business Wire (Pathos AI Series E and collaboration announcements); STAT.